Distinguished in Vasculitis

Kazuyoshi Saito

Okazaki, JP 
Distinguished in Vasculitis
Okazaki, JP 
OverviewLocationsClinical Research

Overview

Kazuyoshi Saito practices in Okazaki, Japan. Mr. Saito is rated as a Distinguished expert by MediFind in the treatment of Vasculitis. His top areas of expertise are Rheumatoid Arthritis (RA), Kawasaki Disease, Arthritis, and Vasculitis.

His clinical research consists of co-authoring 154 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 25 articles in the study of Vasculitis.

Gender
Male

Locations

Okazaki, Japan
Other Locations
Kitakyushu, Japan
Toyoake, Japan
Toyoake, Japan
Tobata, Japan
Nagoya, Japan
Toyama, Japan
Tobata, Japan
Fukuoka, Japan
Hiroshima, Japan
Kobe, 6512271, Japan
Matsuyama, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2

154 Total Publications

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Journal: Drug discoveries & therapeutics
Published: August 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Saito's expertise for a condition
ConditionClose
    View All 54 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile